PURPOSE: To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, and
cisplatin (MIC) chemotherapy in patients with stage IIIB (limited to T4 for pleural effusion and …

Purpose This phase III randomized trial compared two chemotherapy regimens, gemcitabine
plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients …

Purpose This phase III study compared overall survival in patients with locally advanced or
metastatic non–small-cell lung cancer (NSCLC) when treated with single-agent gemcitabine …

BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin,
ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in patients with …

Purpose: This randomized, multicenter, phase III trial was conducted to compare the
tolerability of gemcitabine plus cisplatin (GP) vs. gemcitabine plus carboplatin (GC) in …

Purpose: To compare the therapeutic efficacy of paclitaxel plus cisplatin (arm A) versus
gemcitabine plus cisplatin (arm B) and arm A versus paclitaxel plus gemcitabine (arm C) in …

Background: We conducted a phase II randomized study to assess the efficacy, with
response as the primary endpoint, and the toxicity of gemcitabine/cisplatin (GP) and …

PURPOSE A phase II randomized study was conducted to evaluate the efficacy and toxicity
of gemcitabine (GEM) versus the combination of cisplatin and etoposide (EP) in Chinese …

Background The modest improvement in median survival of advanced non-small-cell lung
cancer (NSCLC) by cisplatin-based chemotherapy has led to the current opinion that clinical …

PURPOSE: The Hoosier Oncology Group has previously reported the results of its phase II
trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients …